Pharmacogenetic aspects of efficacy and safety profile of antidepressants in patients with alcohol dependence
Today it is known that the metabolism involves a number of SSRIs family of isoenzymes of cytochrome P-450, the synthesis of which is encoded by genes having a high degree of polymorphism, which in turn can be associated with changes in the activity of the encoded isoenzymes. Changing the speed biotransformation and elimination of SSRIs, due to the variable activity of isoenzymes, may have an impact on their performance indicators and safety. This review aims to summarize published to date information on the role of pharmacogenetics of antidepressants in order to form a general idea of what gene polymorphism and how can affect the efficacy and safety of treatment of depression in patients with alcohol dependence.